MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Trimodality or Mulitmodality Therapy

Using a combination of treatments, such as chemotherapy, surgery, and radiation. Commonly, preoperative chemotherapy and postoperative radiation.

Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany

Zentralblatt fur Chirurgie 2018 March 12 [Epub ahead of print] [Link] Ried M, Hofmann HS, Dienemann H, Eichhorn M Abstract INTRODUCTION: For several years, hyperthermic intrathoracic chemotherapy (HITHOC) has been performed in a few departments for thoracic surgery in a multimodality treatment regime in addition to surgical cytoreduction. Specific data about HITHOC in Germany are […]

Comments Off on Implementation of Hyperthermic Intrathoracic Chemotherapy (HITHOC) in Germany

18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center

The British Journal of Radiology 2018 March [Epub ahead of print] [Link] H St. AE et.al. Abstract OBJECTIVE: To compare the N and M staging accuracy of positron emission tomography (PET) versus CT, as per the American Joint Committee on Cancer (AJCC) 8th edition in patients with malignant pleural mesothelioma (MPM) being considered for multimodality […]

Comments Off on 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center

Anti-tumor immunotherapy in malignant pleural mesothelioma

Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date. […]

Comments Off on Anti-tumor immunotherapy in malignant pleural mesothelioma

Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania

Future Oncology 2018 February 5 [Link] Spatola C et. al. Abstract The multimodal approach to malignant pleural mesothelioma is gradually becoming the standard of care for this disease in patients with good performance status. Materials & methods: We report our experience concerning eight cases treated with the use of static step-and-shoot intensity-modulated radiotherapy to the […]

Comments Off on Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

Journal of Clinical Oncology 2018 January [Epub ahead of print] [Link] Kindler HL et. al. Abstract Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a […]

Comments Off on Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline

Radical multimodality therapy for malignant pleural mesothelioma

The Cochrane Database of Systematic Reviews 2018 January 8 [Epub ahead of print] [Link] Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M Abstract BACKGROUND: Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum-based chemotherapy is currently the standard treatment. Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy […]

Comments Off on Radical multimodality therapy for malignant pleural mesothelioma

Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma

European Journal of Cardio-Thoracic Surgery 2017 December [Epub ahead of print] [Link] Nelson DB et. al Abstract OBJECTIVES: Malignant pleural mesothelioma is an aggressive and rare malignancy that frequently recurs despite aggressive therapy. We evaluated the frequency of treatment with surgery, radiation or chemotherapy, changes in therapy and survival over time and factors associated with […]

Comments Off on Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in […]

Comments Off on National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

New Concepts in the Treatment of Malignant Pleural Mesothelioma

Annual Review of Medicine 2017 October [Epub ahead of print] [Link] Wald O, Sugarbaker DJ Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive and generally incurable cancer. Current anti-MPM chemotherapy-based treatments are only marginally effective, and long-term survival remains an unmet goal. Nonetheless, in selected cases, personalized surgery-based multimodality treatments (MMT) have been shown […]

Comments Off on New Concepts in the Treatment of Malignant Pleural Mesothelioma

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

Clinical Cancer Research 2017 September [Epub ahead of print][Link] Zauderer MG, et.al. Abstract PURPOSE: Determine the 1-year progression-free survival (PFS) among patients with malignant pleural mesothelioma (MPM) receiving the WT1 peptide vaccine galinpepimut-S after multimodality therapy vs those receiving control adjuvants. PATIENTS AND METHODS: This double-blind, controlled, two center phase II trial randomized MPM patients […]

Comments Off on A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma